AU1768192A - Rna delivery vector - Google Patents
Rna delivery vectorInfo
- Publication number
- AU1768192A AU1768192A AU17681/92A AU1768192A AU1768192A AU 1768192 A AU1768192 A AU 1768192A AU 17681/92 A AU17681/92 A AU 17681/92A AU 1768192 A AU1768192 A AU 1768192A AU 1768192 A AU1768192 A AU 1768192A
- Authority
- AU
- Australia
- Prior art keywords
- delivery vector
- rna delivery
- rna
- vector
- delivery
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Dispersion Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9105465 | 1991-05-03 | ||
| FR919105465A FR2676072B1 (en) | 1991-05-03 | 1991-05-03 | RNA DELIVERY VECTOR. |
| PCT/FR1992/000393 WO1992019752A1 (en) | 1991-05-03 | 1992-04-30 | Rna delivery vector |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU1768192A true AU1768192A (en) | 1992-12-21 |
| AU652831B2 AU652831B2 (en) | 1994-09-08 |
Family
ID=9412502
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU17681/92A Ceased AU652831B2 (en) | 1991-05-03 | 1992-04-30 | RNA delivery vector |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0537326A1 (en) |
| JP (1) | JPH06502998A (en) |
| AU (1) | AU652831B2 (en) |
| CA (1) | CA2086510A1 (en) |
| FR (1) | FR2676072B1 (en) |
| WO (1) | WO1992019752A1 (en) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9320548D0 (en) * | 1993-10-06 | 1993-11-24 | Sandoz Ltd | Improvements in or relating to organic compounds |
| US6472375B1 (en) | 1998-04-16 | 2002-10-29 | John Wayne Cancer Institute | DNA vaccine and methods for its use |
| US6432925B1 (en) * | 1998-04-16 | 2002-08-13 | John Wayne Cancer Institute | RNA cancer vaccine and methods for its use |
| ES2238799T3 (en) * | 1999-09-09 | 2005-09-01 | Curevac Gmbh | RNA-M TRANSFER. |
| ES2646669T3 (en) | 2010-07-06 | 2017-12-14 | Glaxosmithkline Biologicals Sa | Procedures for increasing an immune response by providing RNA |
| ES2557382T3 (en) | 2010-07-06 | 2016-01-25 | Glaxosmithkline Biologicals Sa | Liposomes with lipids that have an advantageous pKa value for RNA delivery |
| EP2591114B1 (en) | 2010-07-06 | 2016-06-08 | GlaxoSmithKline Biologicals SA | Immunisation of large mammals with low doses of rna |
| LT4226941T (en) | 2010-08-31 | 2025-01-10 | Glaxosmithkline Biologicals Sa | Pegylated liposomes for delivery of immunogen-encoding rna |
| WO2012051211A2 (en) * | 2010-10-11 | 2012-04-19 | Novartis Ag | Antigen delivery platforms |
| EP2729165B1 (en) | 2011-07-06 | 2017-11-08 | GlaxoSmithKline Biologicals SA | Immunogenic combination compositions and uses thereof |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| EP3052521A1 (en) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| PL4023249T3 (en) | 2014-04-23 | 2025-03-10 | Modernatx, Inc. | Nucleic acid vaccines |
| US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
| MA42502A (en) | 2015-07-21 | 2018-05-30 | Modernatx Inc | VACCINES AGAINST INFECTIOUS DISEASE |
| JP6948313B6 (en) | 2015-09-17 | 2022-01-14 | モデルナティエックス インコーポレイテッド | Compounds and compositions for intracellular delivery of therapeutic agents |
| WO2017070601A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Nucleic acid vaccines for varicella zoster virus (vzv) |
| WO2017070624A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Tropical disease vaccines |
| AU2016341309A1 (en) | 2015-10-22 | 2018-06-07 | Modernatx, Inc. | Cancer vaccines |
| AU2016342376A1 (en) | 2015-10-22 | 2018-06-07 | Modernatx, Inc. | Sexually transmitted disease vaccines |
| JP7384512B2 (en) * | 2015-10-22 | 2023-11-21 | モデルナティエックス インコーポレイテッド | Broad-spectrum influenza virus vaccine |
| LT3394030T (en) | 2015-12-22 | 2022-04-11 | Modernatx, Inc. | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC SUBSTANCES |
| US11583504B2 (en) | 2016-11-08 | 2023-02-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| MA46766A (en) | 2016-11-11 | 2019-09-18 | Modernatx Inc | INFLUENZA VACCINE |
| WO2018107088A2 (en) | 2016-12-08 | 2018-06-14 | Modernatx, Inc. | Respiratory virus nucleic acid vaccines |
| EP4186888B1 (en) | 2017-03-15 | 2025-11-26 | ModernaTX, Inc. | Compound and compositions for intracellular delivery of therapeutic agents |
| WO2018170256A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Herpes simplex virus vaccine |
| WO2018170322A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Crystal forms of amino lipids |
| WO2018170245A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
| WO2018170270A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Varicella zoster virus (vzv) vaccine |
| EP3595713A4 (en) | 2017-03-15 | 2021-01-13 | ModernaTX, Inc. | RESPIRATORY SYNCYTIAL VIRUS VACCINE |
| CA3055653A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Lipid nanoparticle formulation |
| WO2018232120A1 (en) | 2017-06-14 | 2018-12-20 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
| MA49421A (en) | 2017-06-15 | 2020-04-22 | Modernatx Inc | RNA FORMULATIONS |
| EP3675817A1 (en) | 2017-08-31 | 2020-07-08 | Modernatx, Inc. | Methods of making lipid nanoparticles |
| WO2019055807A1 (en) | 2017-09-14 | 2019-03-21 | Modernatx, Inc. | Zika virus rna vaccines |
| EP3746090A4 (en) | 2018-01-29 | 2021-11-17 | ModernaTX, Inc. | RSV RNA VACCINES |
| WO2020061367A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| WO2020061457A1 (en) | 2018-09-20 | 2020-03-26 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
| US12070495B2 (en) | 2019-03-15 | 2024-08-27 | Modernatx, Inc. | HIV RNA vaccines |
| CN112237628A (en) * | 2019-07-17 | 2021-01-19 | 四川大学华西医院 | EBV-targeted LMP2-mRNA nano vaccine |
| CA3155015A1 (en) | 2019-09-19 | 2021-03-25 | Modernatx, Inc. | Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents |
| AU2020350759A1 (en) | 2019-09-19 | 2022-03-31 | Modernatx, Inc. | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) * | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| FR2598619A1 (en) * | 1986-05-16 | 1987-11-20 | Mafitra Management Services In | Antiviral medicament based on modified nucleic acid, and method for preparing it |
| GB8827592D0 (en) * | 1988-11-25 | 1988-12-29 | Taniguchi T | Improvements in & relating to regulation of expression |
| CA2489769A1 (en) * | 1989-03-21 | 1990-10-04 | Philip L. Felgner | Expression of exogenous polynucleotide sequences in a vertebrate |
-
1991
- 1991-05-03 FR FR919105465A patent/FR2676072B1/en not_active Expired - Fee Related
-
1992
- 1992-04-30 EP EP92910885A patent/EP0537326A1/en not_active Withdrawn
- 1992-04-30 WO PCT/FR1992/000393 patent/WO1992019752A1/en not_active Ceased
- 1992-04-30 CA CA002086510A patent/CA2086510A1/en not_active Abandoned
- 1992-04-30 AU AU17681/92A patent/AU652831B2/en not_active Ceased
- 1992-04-30 JP JP4509832A patent/JPH06502998A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JPH06502998A (en) | 1994-04-07 |
| WO1992019752A1 (en) | 1992-11-12 |
| EP0537326A1 (en) | 1993-04-21 |
| FR2676072B1 (en) | 1994-11-18 |
| FR2676072A1 (en) | 1992-11-06 |
| AU652831B2 (en) | 1994-09-08 |
| CA2086510A1 (en) | 1992-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU1768192A (en) | Rna delivery vector | |
| AU3050892A (en) | Delivery system | |
| AU1966892A (en) | Cosmetic delivery system | |
| AU6733994A (en) | Chondroprotective agents | |
| AU2399092A (en) | Aerosol delivery system | |
| AU6018194A (en) | Easy intubator | |
| AU1967792A (en) | Cosmetic delivery system | |
| AU1823492A (en) | Imidazodiazepines | |
| AU2121092A (en) | Benzodioxanderivate | |
| AU7881091A (en) | Trading discount system | |
| EP0516958A3 (en) | Caffeoyl-coa-3-o-methyltransferase gene | |
| AU1782292A (en) | Gridbeam | |
| AU1930992A (en) | Pyrrolopyrazines | |
| AU2636292A (en) | Anti-alpha6-integrin-antibodies | |
| AU2135292A (en) | Cyanophenylpyrroles | |
| AU1652492A (en) | Game | |
| AU1556892A (en) | 2-substituted-2-imidazolines | |
| AU1080292A (en) | Ige-receptor-antibodies | |
| AU2285592A (en) | Improved coating solution | |
| AU2586192A (en) | Imaginograph | |
| AU1752492A (en) | Diamino-alpha-alkylstilbenes | |
| AU3018192A (en) | Sulfonimidamides | |
| AU6734094A (en) | Chondroprotective agents | |
| AU9073391A (en) | Putter system | |
| AU2040192A (en) | Quinolin-2-yl-methoxybenzylhydroxyureas |